Is Abiraterone Acetate (Zytiga) A Good Alternative for Men with Prostate Cancer Who Are Not Responsive to Androgen Deprivation Therapy (ADT)? 

Men with metastatic prostate cancer (mCRPC) who do not respond to hormone therapy (ADT) or who experience early progression (≤1year) have a poor prognosis.  There is no consensus regarding the proper next therapy for these men.   Abiraterone Acetate (Zytiga) plus prednisone (AA+P) is an effective treatment for men with chemo-naive mCRPC, but limited data are available for poor ADT responders. 

Researchers conducted a study to evaluate the efficacy and safety of AA+P as next treatment for this population. This study is the first to investigate the use of AA+P in poor ADT responders. The study demonstrated a consistent result on PSA response rate with other studies suggesting that AA+P should be considered as an option for initial ADT poor responders.

Joel T. Nowak, MA, MSW wrote this Post.  Joel is the CEO/Executive Director of Cancer ABCs.  He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and the rare cancer Appendiceal cancer.